Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Related Keywords

Carmelo Carlo Stella , ,Department Of Oncology ,Department Of Biomedical Sciences ,Humanitas University ,Humanitas Research Hospital ,Biomedical Sciences ,Research Hospital ,Fda Approval Of Glofitamab ,Patients With Relapsed Refractory Diffuse Largeb Cell Lymphoma ,Phase 1 2 Np30179 Trial ,